Tag

Donanemab

All articles tagged with #donanemab

science12 days ago•70 min saved

Alzheimer’s research gains momentum with new drug approvals and broader targets

Recent advances in Alzheimer’s research include the FDA approval of two drugs, lecanemab and donanemab, which target amyloid plaques and may slow cognitive decline. Scientists are also exploring new targets such as tau proteins, inflammation, and GLP-1-based therapies to improve vascular health and reduce dementia risk. While many treatments remain in early-stage trials, these developments suggest a shift toward a broader and more effective treatment toolkit.

via yahoo.com|

#alzheimers #amyloid-plaques #donanemab

the-highlight1 month ago•34 min saved

Alzheimer’s breakthroughs shift focus to earlier detection and slower decline

New Alzheimer’s drugs lecanemab and donanemab can slow cognitive decline for some patients, and new blood tests may identify at-risk people earlier to enable prevention and treatment; while these advances signal a real shift in how we diagnose and treat dementia, experts caution that benefits are partial, risks remain (including brain bleeds), and a longer, more robust drug pipeline—targeting tau, inflammation, and prevention via GLP-1s—will determine how far we can go. Strong science funding and nonpolitical support for research are crucial as patients are encouraged to discuss testing and trial opportunities with their doctors and to participate in studies.

via vox.com|

#alzheimers #blood-tests #dementia

health5 months ago•4 min saved

Amyloid-targeting Alzheimer’s drugs fall short on patient benefit, review finds

A Cochrane review of 17 trials with over 20,000 people with mild cognitive impairment or early dementia found that seven anti-amyloid drugs, including donanemab and lecanemab, do not deliver a clinically meaningful benefit, even though they reduce brain amyloid. The findings challenge the idea that removing amyloid improves patient outcomes and have fueled ongoing debate over the amyloid hypothesis and the drugs’ high costs and risks.

via ScienceAlert|

#alzheimers #amyloid #clinical-trials

finance2 years ago•3 min saved

FDA Delays Decision on Lilly's Alzheimer's Drug

Eli Lilly and Company's stock declined after the FDA delayed its decision on donanemab, an anti-amyloid beta antibody for early symptomatic Alzheimer's disease. The FDA will convene an advisory committee to discuss the drug's safety and effectiveness based on data from the TRAILBLAZER-ALZ 2 study. The decision, expected in the first quarter of 2024, has been postponed. Meanwhile, other companies like Biogen and GSK are also making strides in the Alzheimer's treatment space.

via Yahoo Finance|

#alzheimers-disease #donanemab #eli-lilly-and-company

healthcare2 years ago•0 min saved

FDA Delays Decision on Eli Lilly's Alzheimer's Drug Donanemab

The US regulator has postponed its decision on Eli Lilly's experimental Alzheimer's drug, donanemab, citing the need for more time to review additional data. The drug has shown promise in slowing the progression of the disease, and the delay in the decision is seen as a setback for the company's efforts to bring a new treatment to market.

via Financial Times|

#alzheimers-drug #decision-delay #donanemab

health2 years ago•2 min saved

"FDA Delays Review of Eli Lilly's Alzheimer's Drug Donanemab"

The FDA has delayed the approval of Eli Lilly's proposed Alzheimer's drug, donanemab, for further review, surprising the company and causing a slight drop in its stock price. The FDA will hold an advisory committee meeting to scrutinize the drug's safety and effectiveness, which targets the amyloid beta substance in the brain linked to Alzheimer's disease. While clinical trials have shown that donanemab slows cognitive decline in early-stage Alzheimer's patients, the drug's logistical constraints and the divisive nature of amyloid-targeting drugs have raised concerns within the medical community.

via The Washington Post|

#alzheimers #amyloid-targeting-drugs #donanemab

healthcare-fda-alzheimers-treatment2 years ago•3 min saved

FDA Delays Approval of Eli Lilly's Alzheimer's Drug, Stock Dips

The FDA has delayed its decision on Eli Lilly's experimental Alzheimer's treatment, donanemab, and plans to convene an advisory meeting to further review its safety and efficacy, reflecting the high stakes of developing treatments for Alzheimer's. The drug significantly slowed Alzheimer's progression in a late-stage trial, but carries safety concerns related to brain swelling and bleeding. This setback comes as Eli Lilly races to compete with Biogen and Eisai, who won approval for their Alzheimer's treatment, Leqembi, last year. Eli Lilly expressed confidence in donanemab's potential benefits and will work with the FDA and stakeholders to address concerns.

via CNBC|

#advisory-panel #alzheimers #donanemab

health-pharmaceuticals2 years ago•2 min saved

FDA Delays Decision on Eli Lilly's Alzheimer's Drug, Donanemab

The FDA has delayed its decision on Eli Lilly's Alzheimer's drug, donanemab, seeking input from its advisory committee to better understand the drug's safety and effectiveness. If approved, it would have been the third drug in a new class aimed at slowing Alzheimer's progression. Concerns about potential side effects and controversies surrounding similar drugs, such as Biogen's Aduhelm, have put the FDA under scrutiny.

via NBC News|

#alzheimers #donanemab #drug-approval

health2 years ago•2 min saved

FDA Postpones Decision on Eli Lilly's Alzheimer's Drug, Prompting Special Committee Meeting

The Food and Drug Administration has unexpectedly delayed the approval of the Alzheimer's drug, donanemab, which was anticipated to be approved this month. Instead, the F.D.A. will convene a panel of independent experts to evaluate the drug's safety and efficacy, surprising both Alzheimer's experts and the drug's maker, Eli Lilly and Company. The decision will postpone any potential approval until at least later this year, with the company hoping for a swift action following the advisory committee's review.

via The New York Times|

#alzheimers #donanemab #drug-approval

health2 years ago•3 min saved

"Concerns Raised Over Potential Side Effects of New Alzheimer's Drugs"

Experts have raised concerns about the potential approval of Alzheimer's drugs donanemab and lecanemab, which have shown to slow the progression of the disease but may also cause brain shrinkage in patients. Trial results indicate that a significant percentage of participants experienced brain swelling or bleeding, leading to warnings about potential serious side effects. While the drugs offer potential benefits, the observed brain volume loss has raised doubts about their overall safety and efficacy.

via Daily Mail|

#alzheimers #brain-shrinkage #donanemab

health3 years ago•9 min saved

"Experts Discuss Pioneering Alzheimer's Treatment and Canada's Readiness for Emerging Therapies"

Researchers have announced that the drug donanemab shows promise in significantly slowing the progression of Alzheimer's disease by clearing toxic amyloid proteins from the brain. While this represents an important breakthrough in dementia research, experts caution that the benefits may be smaller than initially reported, with an average rate of mental decline slowing by around 35%. The drug does not stop the progression of Alzheimer's or improve patients' conditions, but it may provide a few extra months of stability. Donanemab has shown some side effects, including brain swellings and bleeds, and further research is needed to understand the risks and long-term effects. The drug has not yet been approved for use and will undergo further evaluation before becoming available.

via Daily Mail|

#alzheimers-disease #amyloid-hypothesis #dementia-research

health3 years ago•4 min saved

"Promising Alzheimer's Drug Donanemab Offers Hope for Patients"

Trial results of the Alzheimer's drug donanemab show it can slow cognitive decline by 35% in people with early or mild disease. However, the drug is not a cure and has potential risks, including brain swelling. Donanemab has been approved by the US FDA and the manufacturer has applied for approval in Australia. The drug's cost is significant, and its availability may be restricted to those who match the trial population. Early detection and treatment infrastructure need to be developed to facilitate timely diagnosis and treatment.

via The Conversation Indonesia|

#alzheimers-disease #clinical-trial #cognitive-decline

health3 years ago•2 min saved

Breakthrough Alzheimer's Drug Shows Promise in Slowing Cognitive Decline

A new drug called donanemab has shown promising results in a major clinical trial, significantly slowing down cognitive decline in patients with early-stage Alzheimer's disease. While not a cure, the drug could potentially allow individuals suffering from the disease to live longer and less-impeded lives. The treatment, produced by pharmaceutical company Eli Lilly, reduced cognitive decline by approximately 35 percent. However, there are risks associated with the drug, including serious side effects such as brain swelling. Despite this, experts are hailing donanemab as a turning point in the fight against Alzheimer's, offering hope for future treatments that could effectively manage symptoms and improve the quality of life for patients.

via Futurism|

#alzheimers-disease #clinical-trial #cognitive-decline

health3 years ago•2 min saved

Donanemab: A Promising Breakthrough in Alzheimer's Treatment

The final results of the TRAILBLAZER-ALZ 2 study show that donanemab, a disease-modifying therapy for early symptomatic Alzheimer's disease (AD), significantly slows cognitive and functional decline in patients with amyloid-positive AD, regardless of their baseline level of tau. The study found that donanemab reduced amyloid plaque by 84% compared to placebo after 18 months of treatment. Patients who achieved amyloid plaque clearance could stop treatment and still experience lasting benefits. The results support the importance of early diagnosis and treatment for AD, and donanemab has been submitted to the FDA for approval.

via Pharmacy Times|

#alzheimers-disease #amyloid-plaque #clinical-trial

health3 years ago•2 min saved

"Promising Alzheimer's Drug Donanemab Nears FDA Approval, Offers Hope Amidst Side Effects"

Eli Lilly announced that its drug donanemab, which slows the progression of Alzheimer's disease, could receive FDA approval by the end of this year. In a Phase 3 study, donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease, with nearly half of the participants showing no clinical progression after one year. The majority of submissions to global regulators are expected to be completed by year's end. Donanemab would be the second Alzheimer's treatment, after Leqembi, to convincingly delay the disease. However, both drugs come with safety concerns, including brain swelling and bleeding.

via Fox Business|

#alzheimers-disease #cognitive-decline #donanemab